Celcuity Inc. (CELC)
CELC Stock Price Chart
Explore Celcuity Inc. interactive price chart. Choose custom timeframes to analyze CELC price movements and trends.
CELC Company Profile
Discover essential business fundamentals and corporate details for Celcuity Inc. (CELC) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
20 Sept 2017
Employees
87.00
Website
https://www.celcuity.comCEO
Brian F. Sullivan
Description
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.
CELC Financial Timeline
Browse a chronological timeline of Celcuity Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 May 2026
Upcoming earnings on 13 Nov 2025
EPS estimate is -$1.02.
Earnings released on 14 Aug 2025
EPS came in at -$1.04 falling short of the estimated -$0.90 by -15.56%.
Earnings released on 14 May 2025
EPS came in at -$0.86 surpassing the estimated -$0.95 by +9.47%.
Earnings released on 31 Mar 2025
EPS came in at -$0.85 falling short of the estimated -$0.72 by -18.06%, while revenue for the quarter reached $121.34K .
Earnings released on 14 Nov 2024
EPS came in at -$0.70 falling short of the estimated -$0.65 by -7.69%.
Earnings released on 14 Aug 2024
EPS came in at -$0.62 surpassing the estimated -$0.71 by +12.68%.
Earnings released on 15 May 2024
EPS came in at -$0.64 surpassing the estimated -$0.71 by +9.86%.
Earnings released on 27 Mar 2024
EPS came in at -$0.65 surpassing the estimated -$0.71 by +8.45%, while revenue for the quarter reached $229.65K .
Earnings released on 13 Nov 2023
EPS came in at -$0.83 falling short of the estimated -$0.74 by -12.16%.
Earnings released on 10 Aug 2023
EPS came in at -$0.66 surpassing the estimated -$0.67 by +1.49%.
Earnings released on 15 May 2023
EPS came in at -$0.55 surpassing the estimated -$0.65 by +15.38%.
Earnings released on 23 Mar 2023
EPS came in at -$0.69 falling short of the estimated -$0.54 by -27.78%.
Earnings released on 10 Nov 2022
EPS came in at -$0.75 falling short of the estimated -$0.49 by -53.06%.
Earnings released on 11 Aug 2022
EPS came in at -$0.67 falling short of the estimated -$0.47 by -42.55%.
Earnings released on 16 May 2022
EPS came in at -$0.53 falling short of the estimated -$0.51 by -3.92%.
Earnings released on 23 Mar 2022
EPS came in at -$0.45 falling short of the estimated -$0.40 by -12.50%.
Earnings released on 8 Nov 2021
EPS came in at -$0.41 falling short of the estimated -$0.35 by -17.14%.
Earnings released on 9 Aug 2021
EPS came in at -$1.11 falling short of the estimated -$0.38 by -192.11%.
Earnings released on 10 May 2021
EPS came in at -$0.25 falling short of the estimated -$0.20 by -25.00%.
Earnings released on 16 Feb 2021
EPS came in at -$0.25 falling short of the estimated -$0.23 by -8.70%.
Earnings released on 9 Nov 2020
EPS came in at -$0.20 surpassing the estimated -$0.21 by +4.76%.
CELC Stock Performance
Access detailed CELC performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.